Tom Dunlap – chairman
Tom Dunlap has brought rapid growth and positive change to many ophthalmic medical device companies. As a senior executive and leader in the ophthalmic industry, he has led entrepreneurial ventures and multinational healthcare companies. He has held executive positions at American Hospital Supply Corporation, Coherent, Inc., Allergan Medical Optics, Bausch + Lomb, Inc. and HOYA Surgical Optics. He served on the Outpatient Ophthalmic Surgical Society Board, ASCRS Foundation Board, Ocular Surgery News Industry Advisory Council, Ophthalmology Innovation Summit Advisory Board and Ophthalmology Futures Forum Asia Advisory Board. Tom holds a MBA with honors from the University of Southern California, Los Angeles, California and a BA from Ashland University, Ashland, Ohio.
Patrick Krol is managing partner at Aescap Venture, a venture capital company investing in private medical companies in Europe. From 1995 until 2005 Patrick guided 35 pharma and biotech companies to successfully introduce or expand their products. In 2003 Patrick received an MBA in Executive Management and Consultancy. In the same year he became a visiting teacher of the University of Wageningen business school teaching ‘Strategy in the Pharmaceutical Industry’, and published several articles on pharma/biotech marketing strategy. Since 2004 he holds a board seat at Shire Pharmaceuticals International Licensing. Patrick joined Aescap since its inception in 2005 and serves on the supervisory boards of Aquapharm BioDiscovery, f-Star, i-Optics and to-BBB.
Dr Chandra P. Leo
Chandra Leo has more than 15 years of experience in private equity, clinical practice and biomedical research. He completed his medical studies in Berlin and London and holds a doctoral degree in medicine from the Freie Universität Berlin (Charité) and an MBA degree with distinction from INSEAD. He worked as a postdoctoral scientist at Stanford University and as a physician at the University Hospital Leipzig in Germany, before moving into venture capital/private equity, first at Wellington Partners and today at HBM Partners. Chandra served as a board representative at Anthera Pharmaceuticals (IPO NASDAQ), ChemoCentryx (IPO NASDAQ), ESBATech (acquired by Alcon/Novartis) and Panomics (acquired by Affymetrix). He is currently a board member at CardiacAssist, Delenex Therapeutics, Gynesonics and i-Optics and a board observer at Odyssey Thera.
Pieter van der Meijden
Pieter holds an MSc degree in Business Economics from the Rotterdam Erasmus University. In 1980 he joined the De Nationale Investeringsbank (currently NIBC) where he took senior account management roles in commercial banking and investments. In 1995 he became managing director at Halder Invest (currently part of GIMV). In 2003 he joined the Berk Partners investment company to become managing partner, with a focus on MBOs and later stage expansion finance. Since 2007 he is a management team member of the Hoge Dennen Holding family office.